Ascendo Biotechnology was honored to participate as an invited speaker at the Healthcare Conference Taipei 2025, held from February 19–20, 2025, at the Regent Taipei Hotel. The event was co-hosted by J.P. Morgan and the University of California, Berkeley School of Public Health, bringing together global leaders in healthcare investment, biotechnology, and medical innovation.
Ascendo Biotechnology presented its lead clinical asset, ASD141, a novel innate immune checkpoint inhibitor currently in Phase I trials for solid tumors, and introduced ASD001, a preclinical monoclonal antibody targeting autoimmune diseases such as inflammatory bowel disease (IBD) and systemic lupus erythematosus (SLE). Both programs are rooted in the company’s deep expertise in innate immunity and its commitment to transforming the treatment landscape in oncology and immunology.
The invitation to present at a conference co-organized by J.P. Morgan, one of the most influential institutions in global healthcare and life sciences investment, represents a significant recognition of Ascendo Biotechnology’s innovation and therapeutic potential.
Ascendo Biotechnology continues to advance a robust pipeline of immunomodulatory therapies and remains dedicated to delivering transformative solutions for patients with high unmet medical needs.